These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 788002)

  • 1. Effect of lithium on neuroleptic-induced tardive dyskinesia compared with placebo in a double-blind cross-over trial.
    Gerlach J; Thorsen K; Munkvad I
    Pharmakopsychiatr Neuropsychopharmakol; 1975 Mar; 8(2):51-6. PubMed ID: 788002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical observations of the treatment of tardive dyskinesia with haloperidol.
    Frangos E; Christodoulides H
    Acta Psychiatr Belg; 1975 Jan; 75(1):19-32. PubMed ID: 785948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lithium in tardive dyskinesia.
    Simpson GM; Branchey MH; Lee JH; Voitashevsky A; Zoubok B
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Mar; 9(2):76-80. PubMed ID: 790411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lithium carbonate in the treatment of tardive dyskinesia.
    Reda FA; Escobar JI; Scanlan JM
    Am J Psychiatry; 1975 May; 132(5):560-2. PubMed ID: 804260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baclofen (Lioresal) in the treatment ofneuroleptic-induced tardive dyskinesia.
    Korsgaard S
    Acta Psychiatr Scand; 1976 Jul; 54(1):17-24. PubMed ID: 782159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology of tardive dyskinesia. Part II.
    Jus A; Pineau R; Lachance R; Pelchat G; Jus K; Pires P; Villeneuve R
    Dis Nerv Syst; 1976 May; 37(5):257-61. PubMed ID: 1261344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients.
    Ghadirian AM; Annable L; Bélanger MC; Chouinard G
    J Clin Psychiatry; 1996 Jan; 57(1):22-8. PubMed ID: 8543543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deanol, lithium and placebo in the treatment of tardive dyskinesia. A double-blind crossover study.
    Jus A; Villeneuve A; Gautier J; Jus K; Villeneuve C; Pires P; Villeneuve R
    Neuropsychobiology; 1978; 4(3):140-9. PubMed ID: 340975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind carbidopa/levodopa and placebo study in tardive dyskinesia.
    Simpson GM; Yadalam KG; Stephanos MJ
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):49S-51S. PubMed ID: 2906069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylphenidate in tardive dyskinesia.
    Fann WE; Davis JM; Wilson IC
    Am J Psychiatry; 1973 Aug; 130(8):922-4. PubMed ID: 4577471
    [No Abstract]   [Full Text] [Related]  

  • 12. [A double-blind study of the effect of L-dopa in psychotic patients with tardive dyskinesia].
    Karniol IG; Giampietro AC; Moura DS; Vilela WA; Oliveira MA; Zuardi AW
    Acta Psiquiatr Psicol Am Lat; 1983 Dec; 29(4):261-6. PubMed ID: 6369888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
    Silver H; Geraisy N; Schwartz M
    J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment.
    Gerlach J; Thorsen K
    Int Pharmacopsychiatry; 1976; 11(1):1-7. PubMed ID: 770362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of clonidine in the treatment of neuroleptic-induced tardive dyskinesia.
    Browne J; Silver H; Martin R; Hart R; Mergener M; Williams P
    J Clin Psychopharmacol; 1986 Apr; 6(2):88-92. PubMed ID: 2871058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.
    O'Brien CF; Jimenez R; Hauser RA; Factor SA; Burke J; Mandri D; Castro-Gayol JC
    Mov Disord; 2015 Oct; 30(12):1681-7. PubMed ID: 26346941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.
    Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):761-4. PubMed ID: 18201810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tardive Dyskinesia induced by neuroleptics: a survey of 3140 patients in a psychiatric hospital].
    Bourgeois M
    Encephale; 1977; 3(4):299-320. PubMed ID: 611013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine.
    Kazamatsuri H; Chien CP; Cole JO
    Am J Psychiatry; 1973 Apr; 130(4):479-83. PubMed ID: 4570750
    [No Abstract]   [Full Text] [Related]  

  • 20. [Vitamin B6 add-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders].
    Miodownik C; Cohen H; Kotler M; Lerner V
    Harefuah; 2003 Sep; 142(8-9):592-6, 647. PubMed ID: 14518160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.